Published Research

Sunstone leads and supports FDA-approved clinical trials in collaboration with top-tier research sponsors, academic institutions, and healthcare systems. Our studies cover a diverse set of psychedelic compounds and mental health indications, including trauma-related disorders, mood conditions, and end-of-life distress.
01
Sunstone designs and delivers innovative clinical trials with leading psychedelic drug developers and medical bodies.
  • atai Life Sciences
  • Beckley Psytech
  • COMPASS Pathways
  • Cybin
  • Lykos Therapeutics
  • MindMed
  • Reunion Neuroscience
  • Transcend Therapeutics
  • Usona Institute
02
We work with a broad range of psychedelics.
  • Psilocybin
  • MDMA
  • LSD
  • 5-MeO-DMT
  • Methylone
  • RE-104 (serotonergic antidepressant)
03
Across a wide array of clinical indications.
  • Adjustment Disorder (AD)
  • Demoralization in Patients with Cancer
  • Palliative Care (Advanced Illness)
  • Generalized Anxiety Disorder (GAD)
  • Major Depressive Disorder (MDD)
  • Major Depressive Disorder in Patients with Cancer
  • Post-Traumatic Stress Disorder (PTSD)
  • Postpartum Depression
  • Treatment-Resistant Depression (TRD)
04
In partnership with top-tier academic and medical institutions.
  • Adventist HealthCare
  • Dana-Farber Cancer Institute
  • Johns Hopkins Center for Psychedelic & Consciousness Research
  • McGill University
  • Memorial Sloan Kettering Cancer Center
  • The University of Vermont

Sunstone Published Research

Explore our growing list of published research featured in medical journals and publications.

New Clinical Study Enrolling for Major Depressive DisorderLearn More
+